tiprankstipranks
Idexx Laboratories (CH:IX1)
:IX1
Switzerland Market

Idexx Laboratories (IX1) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

IX1 Analyst Ratings

Moderate Buy
7Ratings
Moderate Buy
4 Buy
3 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Idexx
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IX1 Stock 12 Month Forecast

Average Price Target

Based on 7 Wall Street analysts offering 12 month price targets for Idexx Laboratories in the last 3 months. The average price target is CHF563.00 with a high forecast of CHF648.22 and a low forecast of CHF535.49. The average price target represents a change from the last price of .
eyJuYXZpZ2F0b3IiOnsiZGlzYWJsZWQiOnRydWV9LCJleHBvcnRpbmciOnsiZW5hYmxlZCI6ZmFsc2V9LCJ0aXRsZSI6eyJ0ZXh0IjpudWxsfSwiY2hhcnQiOnsiaGVpZ2h0IjoyMDAsInN0eWxlIjp7ImZvbnRGYW1pbHkiOiJSb2JvdG8gRmxleCwgLWFwcGxlLXN5c3RlbSwgQmxpbmtNYWNTeXN0ZW1Gb250LCBTZWdvZSBVSSwgUm9ib3RvLCBIZWx2ZXRpY2EsIEFyaWFsLCBzYW5zLXNlcmlmLCBBcHBsZSBDb2xvciBFbW9qaSwgU2Vnb2UgVUkgRW1vamksIFNlZ29lIFVJIFN5bWJvbCIsImZvbnRXZWlnaHQiOiI0MDAiLCJjb2xvciI6IiM1ZDVkNWUifX0sInlBeGlzIjp7ImxhYmVscyI6eyJzdHlsZSI6eyJjb2xvciI6ImluaGVyaXQifX0sInZpc2libGUiOmZhbHNlfSwicGxvdE9wdGlvbnMiOnsic2VyaWVzIjp7InN0YXRlcyI6eyJpbmFjdGl2ZSI6eyJvcGFjaXR5IjoxfX19fSwieEF4aXMiOnsibGFiZWxzIjp7InN0eWxlIjp7ImNvbG9yIjoiaW5oZXJpdCJ9fSwidmlzaWJsZSI6ZmFsc2V9LCJsZWdlbmQiOnsic3ltYm9sUmFkaXVzIjowLCJzeW1ib2xQYWRkaW5nIjo0LCJzeW1ib2xIZWlnaHQiOjE0LCJib3JkZXJXaWR0aCI6MCwic3ltYm9sV2lkdGgiOjE0LCJhbGlnbiI6ImxlZnQiLCJ2ZXJ0aWNhbEFsaWduIjoiYm90dG9tIiwiZW5hYmxlZCI6ZmFsc2V9LCJ0b29sdGlwIjp7ImJhY2tncm91bmRDb2xvciI6IndoaXRlIn0sImNyZWRpdHMiOnsiZW5hYmxlZCI6ZmFsc2V9LCJhY2Nlc3NpYmlsaXR5Ijp7ImRlc2NyaXB0aW9uIjoiIn0sInNlcmllcyI6W3sidHlwZSI6ImFyZWEiLCJkYXRhIjpbXX1dfQ==
Highest Price TargetCHF648.22Average Price TargetCHF563.00Lowest Price TargetCHF535.49
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CH:IX1
Bank of America Securities
Bank of America Securities
CHF531.46CHF535.49
Hold
Reiterated
08/14/26
Idexx: Neutral Stance Maintained as Long-Term Outlook Stays Opaque, Target Price Raised to $665
Stifel Nicolaus Analyst forecast on CH:IX1
Stifel Nicolaus
Stifel Nicolaus
CHF543.54
Buy
Reiterated
08/14/26
Analysts Are Bullish on Top Healthcare Stocks: Idexx Laboratories (IDXX), Nkarta (NKTX)
William Blair Analyst forecast on CH:IX1
William Blair
William Blair
Buy
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (NASDAQ: ACHV) and Idexx Laboratories (NASDAQ: IDXX)
Barclays
CHF571.72
Buy
Reiterated
08/11/26
Idexx Laboratories (IDXX) Receives a Buy from Barclays
Morgan Stanley Analyst forecast on CH:IX1
Morgan Stanley
Morgan Stanley
CHF648.22
Buy
Reiterated
08/05/26
Idexx Laboratories (IDXX) Receives a Buy from Morgan Stanley
UBS
CHF499.25CHF539.51
Hold
Reiterated
08/05/26
UBS Sticks to Its Hold Rating for Idexx Laboratories (IDXX)
Citi
CHF523.41CHF539.51
Hold
Reiterated
08/05/26
Citi Keeps Their Hold Rating on Idexx Laboratories (IDXX)
Jefferies Analyst forecast on CH:IX1
Jefferies
Jefferies
CHF637.75
Buy
Reiterated
05/06/26
Idexx Laboratories (IDXX) Receives a Buy from Jefferies
Piper Sandler Analyst forecast on CH:IX1
Piper Sandler
Piper Sandler
CHF624.06CHF603.93
Hold
Reiterated
02/09/26
Idexx Laboratories price target lowered to $750 from $775 at Piper SandlerIdexx Laboratories price target lowered to $750 from $775 at Piper Sandler
BTIG
CHF668.35CHF644.2
Buy
Reiterated
02/03/26
Idexx Laboratories price target lowered to $800 from $830 at BTIGIdexx Laboratories price target lowered to $800 from $830 at BTIG
J.P. Morgan Analyst forecast on CH:IX1
J.P. Morgan
J.P. Morgan
CHF624.06
Buy
Reiterated
11/03/25
J.P. Morgan Keeps Their Buy Rating on Idexx Laboratories (IDXX)
Leerink Partners Analyst forecast on CH:IX1
Leerink Partners
Leerink Partners
CHF599.91CHF632.12
Buy
Reiterated
11/03/25
Idexx Laboratories price target raised to $785 from $745 at LeerinkIdexx Laboratories price target raised to $785 from $745 at Leerink
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CH:IX1
Bank of America Securities
Bank of America Securities
CHF531.46CHF535.49
Hold
Reiterated
08/14/26
Idexx: Neutral Stance Maintained as Long-Term Outlook Stays Opaque, Target Price Raised to $665
Stifel Nicolaus Analyst forecast on CH:IX1
Stifel Nicolaus
Stifel Nicolaus
CHF543.54
Buy
Reiterated
08/14/26
Analysts Are Bullish on Top Healthcare Stocks: Idexx Laboratories (IDXX), Nkarta (NKTX)
William Blair Analyst forecast on CH:IX1
William Blair
William Blair
Buy
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (NASDAQ: ACHV) and Idexx Laboratories (NASDAQ: IDXX)
Barclays
CHF571.72
Buy
Reiterated
08/11/26
Idexx Laboratories (IDXX) Receives a Buy from Barclays
Morgan Stanley Analyst forecast on CH:IX1
Morgan Stanley
Morgan Stanley
CHF648.22
Buy
Reiterated
08/05/26
Idexx Laboratories (IDXX) Receives a Buy from Morgan Stanley
UBS
CHF499.25CHF539.51
Hold
Reiterated
08/05/26
UBS Sticks to Its Hold Rating for Idexx Laboratories (IDXX)
Citi
CHF523.41CHF539.51
Hold
Reiterated
08/05/26
Citi Keeps Their Hold Rating on Idexx Laboratories (IDXX)
Jefferies Analyst forecast on CH:IX1
Jefferies
Jefferies
CHF637.75
Buy
Reiterated
05/06/26
Idexx Laboratories (IDXX) Receives a Buy from Jefferies
Piper Sandler Analyst forecast on CH:IX1
Piper Sandler
Piper Sandler
CHF624.06CHF603.93
Hold
Reiterated
02/09/26
Idexx Laboratories price target lowered to $750 from $775 at Piper SandlerIdexx Laboratories price target lowered to $750 from $775 at Piper Sandler
BTIG
CHF668.35CHF644.2
Buy
Reiterated
02/03/26
Idexx Laboratories price target lowered to $800 from $830 at BTIGIdexx Laboratories price target lowered to $800 from $830 at BTIG
J.P. Morgan Analyst forecast on CH:IX1
J.P. Morgan
J.P. Morgan
CHF624.06
Buy
Reiterated
11/03/25
J.P. Morgan Keeps Their Buy Rating on Idexx Laboratories (IDXX)
Leerink Partners Analyst forecast on CH:IX1
Leerink Partners
Leerink Partners
CHF599.91CHF632.12
Buy
Reiterated
11/03/25
Idexx Laboratories price target raised to $785 from $745 at LeerinkIdexx Laboratories price target raised to $785 from $745 at Leerink
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Idexx Laboratories

3 Months
Daniel ClarkLeerink Partners
Success Rate
7/9 ratings generated profit
78%
Average Return
+7.60%
Copying Daniel Clark's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +7.60% per trade.
1 Year
Jonathan BlockStifel Nicolaus
Success Rate
26/36 ratings generated profit
72%
Average Return
+24.60%
Copying Jonathan Block's trades and holding each position for 1 Year would result in 72.22% of your transactions generating a profit, with an average return of +24.60% per trade.
2 Years
Success Rate
7/10 ratings generated profit
70%
Average Return
+11.68%
Copying Mark Massaro's trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +11.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IX1 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
8
6
5
6
7
Hold
10
6
5
3
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
12
10
9
12
In the current month, IX1 has received 7 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. IX1 average Analyst price target in the past 3 months is 563.00.
Each month's total comprises the sum of three months' worth of ratings.

IX1 Financial Forecast

IX1 Earnings Forecast

Next quarter’s earnings estimate for IX1 is CHF3.02 with a range of CHF2.96 to CHF3.06. The previous quarter’s EPS was CHF3.48. IX1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IX1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for IX1 is CHF3.02 with a range of CHF2.96 to CHF3.06. The previous quarter’s EPS was CHF3.48. IX1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IX1 has Performed in-line its overall industry.

IX1 Sales Forecast

Next quarter’s sales forecast for IX1 is CHF969.28M with a range of CHF962.65M to CHF979.78M. The previous quarter’s sales results were CHF990.40M. IX1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IX1 has Performed in-line its overall industry.
Next quarter’s sales forecast for IX1 is CHF969.28M with a range of CHF962.65M to CHF979.78M. The previous quarter’s sales results were CHF990.40M. IX1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IX1 has Performed in-line its overall industry.

IX1 Stock Forecast FAQ

What is CH:IX1’s average 12-month price target, according to analysts?
Based on analyst ratings, Idexx Laboratories’s 12-month average price target is 563.00.
    What is CH:IX1’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:IX1, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Idexx Laboratories a Buy, Sell or Hold?
        Idexx Laboratories has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 3 hold ratings and 0 sell ratings.
          What is Idexx Laboratories’s share price target?
          The average share price target for Idexx Laboratories is 563.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF648.22 ,and the lowest forecast is CHF535.49. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Idexx Laboratories?
            Idexx Laboratories’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
              How can I buy shares of Idexx Laboratories?
              To buy shares of CH:IX1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.